US20020182243A1 - Method of producing nutritional products from human milk tissue and compositions thereof - Google Patents

Method of producing nutritional products from human milk tissue and compositions thereof Download PDF

Info

Publication number
US20020182243A1
US20020182243A1 US10/144,325 US14432502A US2002182243A1 US 20020182243 A1 US20020182243 A1 US 20020182243A1 US 14432502 A US14432502 A US 14432502A US 2002182243 A1 US2002182243 A1 US 2002182243A1
Authority
US
United States
Prior art keywords
human milk
milk
sample
collection
feeding tube
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/144,325
Inventor
Elena Medo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolacta Bioscience Inc
Original Assignee
Medo Elena Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US29082301P priority Critical
Application filed by Medo Elena Maria filed Critical Medo Elena Maria
Priority to US10/144,325 priority patent/US20020182243A1/en
Publication of US20020182243A1 publication Critical patent/US20020182243A1/en
Assigned to PROLACTA BIOSCIENCE, INC. reassignment PROLACTA BIOSCIENCE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDO, ELENA MARIA
Priority claimed from US12/728,811 external-priority patent/US20100268658A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER, CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/20Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A23C9/206Colostrum; Human milk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Abstract

Methods of isolating, treating, storing and processing human milk, as well as nutritional formulations of human milk comprising protective human milk proteins.

Description

  • This application claims priority to U.S. Provisional Patent Application Serial No. 60/290,823, filed May 14, 2001.[0001]
  • FIELD OF THE INVENTION
  • The present invention relates to biopharmaceutical and nutritional products obtained from human milk and mammary gland secretions. More particularly, the present invention relates to methods of isolating, storing, transferring, processing, packaging and delivering pharmaceutical and nutritional formulations comprising cells and tissues of human milk, fractionated human milk components and specifically reunited components of human milk. One embodiment of the present invention relates to improving the nutrition of low birth weight infants. Another embodiment of the present invention relates to a novel type of immunoglobulin useful in treating disorders, such as, for example, cancer, immune disorders, gastrointestinal disorders, nutritional disorders and metabolic disorders. [0002]
  • BACKGROUND OF THE INVENTION
  • The lack of a standardized source of human milk, available for research purposes, has seriously hampered scientific investigation of human milk as well as the majority of the nearly 4,000 unique, species-specific milks. Accordingly, it would be desirable to provide a standardized source of human milk that can be modified to reflect the various stages of lactation and various immune responses. [0003]
  • Although the presence of immunoglobulins in human milk has been acknowledged for a number of years, the specific role and function of each of the human milk immunoglobulins and their subclasses has been poorly understood. For the patient of any age suffering from an immune disorder, the worldwide gamma globulin shortage is impacting care to such a degree that some patients are unable to obtain treatment. Purified immunoglobulins from human milk hold the potential for a solution for this worldwide shortage. Accordingly, it would be desirable to provide formulations comprising higher levels of immunoglobulins isolated from human milk, as well as methods to deliver these formulations to patients. [0004]
  • It has been known for a long time by physicians, scientists and nutritionists that the best food or nutrition supplied to an infant is its own mother's milk, i.e., fresh human milk. Recent research has indicated that “species-specific” milk plays a significant role in disease prevention and the severity of disease when the infant does become ill. Until recently, the reasons behind the superiority of species-specific milk were not well understood, nor were the various components and the roles they play in development and disease prevention. It is recognized, however, that many situations arise wherein the infant cannot obtain its mother's milk and as a result a suitable replacement is desired. Artificial baby milks, predominantly based on cow's milk, have been prepared and used to nourish an infant but there is increasing evidence that infants fed artificial baby milks suffer long-term ill consequences. It has been suggested that the exposure of an infant to any foreign proteins, such as the bovine protein, during the first few days of life will increase the infant's chance of becoming afflicted with juvenile diabetes. Other ill effects include allergies, lowered immunity, gastrointestinal disorders, respiratory disease and other associated etiology. Although much effort has been made to improve synthetic infant milk formulas, attempting to make them more closely simulate mother's milk, the presence of living organisms and other “species-specific” cells that act in a way to trigger other disease preventing mechanisms in the infant, these efforts have proven futile. [0005]
  • According to Jenness and Sloan, human milk contains three major groups of constituents that carry strong “species-specific” and “organ-specific” missions: (1) constituents specific to both organ and species, including proteins and lipids; (2) constituents specific to organ but not species, including lactose; and (3) constituents specific to species but not to organ, including albumin and some immunoglobulins. [0006]
  • Human milk is not a uniform body fluid; instead, it is a secretion from the mammary gland of constantly changing composition. In nature, the composition of human milk changes not only from day to day, but also throughout the course of a single day. While the reasons and outcome of these changes are not fully understood, it is intuitive to believe that these changes benefit the-species and that substantial advantages may be gained for the infant who is provided an opportunity to reap the benefits of a modified formulation of 100% human milk. Accordingly, it would be desirable to provide formulations comprising human milk proteins as nutritional supplements and therapeutics for patients in need of gamma globulin therapy. [0007]
  • SUMMARY OF THE INVENTION
  • Compositions containing [0008] 100% human milk proteins, including the so-called host resistance factors (HRF) of human milk, as well as other nutrients, living cells, and components are useful when employed to enhance and improve outcomes for babies and children who are not able to obtain human milk from their mothers (or cannot obtain enough mother's milk or mother's milk in the formulation needed due to immunodeficiency of the mother) as well as other patients (including adults) suffering from immune disorders, nutritional disorders and other diseases and dietary challenges.
  • The sequential administration of many of the human milk constituents provides substantial value to the recipient because of metabolic and catabolic processes. It is at the core of the present invention to utilize such human milk constituents, in their processed form, in such a sequential fashion as to provoke the same type of chain reaction in the body. With this concept, the pairing of the processed milk tissue with the sequential and differentiated delivery methods, patients may enjoy a new type of preventative and therapeutic medicine. Because human milk immunoglobulins are specifically targeted to many diseases of the newborn, as well as the protective functions of the mucus membranes of the newborn's body, and contain higher levels of IgA, IgD, IgM and IgE, the term “panoglobulin” or “lactapanoglobulin” has been coined for this newly identified formulation. In addition to fighting immune disorders with a human-milk origin panaglobulin, patients preparing for surgery, chemotherapy, radiation or other “currently accepted, but destructive” therapies, may enjoy preliminary therapies that may mitigate the ill effects of their upcoming procedure. In the same fashion, the constantly changing nature of species-specific milk allows for the inclusion of the mammary gland as a laboratory of sorts, seeking not to-simply initiate and artificially replicate structures like antibodies and proteins, but instead, to produce a bonafide human-produced fluid that can be isolated, processed and delivered for a highly targeted use against disease. [0009]
  • One embodiment of the present invention provides a nutritional formulation of isolated human milk containing protective human milk proteins or host resistance factors of human milk suitable for infant consumption which can be directly administered to an infant. [0010]
  • Another embodiment of the present invention provides a method of isolating human milk comprising the steps of collecting a sample of human milk from a donor in a collection device, storing the sample of milk obtained from the donor, and processing the milk sample by conducting a nutritional analysis on the milk sample; fortifying the sample with heat-resistant nutrients, pasteurizing the sample; fortifying the pasteurized sample with heat-sensitive nutrients and testing the sample to ensure successful pasteurization. [0011]
  • Yet another embodiment of the present invention provides a system for delivering human milk to an infant. The system contains a feeding tube treated to minimize adherence of milk fat to the interior of the feeding tube; a heated sheath surrounding the feeding tube and an enteral pump removably mounted to a motorized platform. [0012]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention and the methods of obtaining and using the present invention will be described in detail after setting forth preliminary definitions. [0013]
  • Definitions [0014]
  • The following definitions are provided to facilitate understanding of certain terms used in the present invention. [0015]
  • As used herein, “human-milk” means-any stage of human-milk production including the production of breast secretions not associated with lactation. These stages include, but are not limited to, colostrums, transitional milk and mature milk. [0016]
  • As used herein, “species-specific milk” means any milk that would be processed or formulated to provide an advantage of any kind to its own offspring. [0017]
  • As used herein, “second-best species-specific milk” means any milk that would be processed or formulated to provide a “close second” to its own species-specific milk resulting in better outcomes than using the standard bovine or soy based milk replacer. [0018]
  • The present invention describes a method that includes multiple steps and processes to harvest or isolate, store, transfer, process, package and deliver a variety of pharmaceutical and nutritional formulations containing cells and tissues comprising 100% human milk tissue, fractionated human milk tissue components and specifically reunited compounds, as well as novel methods and procedures to affect levels of such fractionated human milk tissue components, isolate them from raw human milk and deliver them through various methods including (but not limited to) ingestion, inhalation, intra-nasal administration, eye drops, ear drops, enema, douche, lavage, transdermally, rectally, intravenously, intramuscularly injection, direct injection, direct topical application, ng tube and jg tube. [0019]
  • Additionally, these formulations may be delivered through any of these methods, but when delivered, the present invention describes a sequence of delivery by which certain components or compounds will catabolize to create optimum conditions for the sequential delivery of an additional compound. For instance, if the formulation is nutritionally focused, the present invention provides a formulation that is specifically delivered in the morning, with a different formulation delivered in the afternoon and evening. [0020]
  • Little is understood at this time, as to why the formulation of mammalian milk evolves throughout the day. The present invention is directed to a method by which this differentiation is preferred and would create an improved outcome for the patient. Additionally, by any method, there may be an advantage to the “priming” of the patient by the delivery of certain processed human milk components, thereby eliciting a response in the patient's body that will improve outcomes when the next treatment in the sequence is followed. This sequential treatment concept would not be limited to the method of delivery. Instead, the present invention relates to the possibility that multiple delivery methods may actually trigger multiple advantageous responses in the patient, increasing the patients' chance of an improved outcome by coaxing the patient's system into active collaboration with the treatment method. This method simulates the natural processes of the mammalian immune system, which cannot be described as any one “silver bullet” but a series of complex communications between multiple cell structures and the offending pathogen. [0021]
  • The present invention relates to use of the disclosed methods and formulations from all mammalian species and is not limited to human beings. Additionally, the present invention encompasses all breast fluids as a potential source for harvesting milk and immune cells, as the mammary gland is a lymphoid organ, capable of producing immunoglobulins with or without accompanying lactation.[0022]
  • EXAMPLES
  • The following examples are intended to illustrate various embodiments of the present invention and are not to be construed as limiting the scope of the invention. [0023]
  • Example 1 Gamma Globulin Formulations
  • At the center of this invention, is the intent to solve the worldwide shortage of gamma globulin. The current source of gamma globulin is blood serum, and specifically IgG from human blood. The present invention discloses a prophetic inclination, based upon a 15-year study of human milk, that a new form of gammaglobulin referred to herein as “panaglobulin,” “mammaglobulin” or “lactopanaglobulin” may replace the current gamma globulin. Because higher levels of IgA and IgM are present in human milk and colostrums, and a more diverse form of TgG as well, panaglobulins may provide protection beyond the scope of current gamma globulin therapy. Manipulation of the levels of immunoglobulins and their subclasses will result in formulations that are targeted at specific diseases or organ systems, making it possible to attack disease using nature's pharmaceutical laboratory, the mammary gland. Furthermore, milk donors who have weaned their babies or have initiated lactation without pregnancy could feasibly become human labs, becoming exposed through any method to mild strains of disease and producing the appropriate antibody in their milk. Since the breast is reactive to new exposures of pathogens, an array of new immunities can be produced to combat such diseases. Whether these types of donors could produce enough milk to become a primary source remains to be seen, but at least these donors could provide a human lab for biosynthesizing disease specific antibodies that could be replicated later using other methods. [0024]
  • Colostrum contains high levels of immunoglobulins, a vital defense mechanism that protects the newly born. sIgA provides immediate protection to the infant by lining the gastrointestinal system and providing a first defense against dangerous pathogens like [0025] E. coli and other devastating disease organisms. The invention discloses concentrated, processed sIgA for use as a prevention or therapeutic for gut disorders in patients of all ages. Potency levels will depend upon the severity of the disease, the general health of the patient and the cost of the processing.
  • Colostrum also contains IgG1, G2, G3, G4, IgM, IgD and trace amounts of other human origin immunoglobulins. All of these immunoglobulins function in a myriad of ways, targeting specific organs and disease states. Because the mammary gland is a lymphoid organ, it is capable of synthesizing immunoglobulins, especially the four IgG subclasses, making it possible to achieve a higher level of IgG subclasses in breast fluid than is present in human blood serum. This capability of the mammary gland is not limited to lactation, with measurable quantities of IgG present in breast ductal fluid from non-lactating women. Expressing ductal fluid may provide protective advantages to the donor, specifically the cleansing of the breast ductal system, as disclosed in a prior patent application by the inventor. This invention envisions breast fluid from non-lactating women as a potential source of human immunoglobulins. Current research cites a wide variety of volume and constituents present in colostrums, transitional milk and mature milk but little information exists for the constituents present in the breast ductal fluid of non-lactating women. The present invention is directed to the ability to influence the volume and constituents of breast ductal fluid through dietary and pharmaceutical manipulation. [0026]
  • For nutritional and pharmaceutical applications, other valuable proteins contained in human milk include alpha-lactalbumin, beta-lactoglobulin, lactoferrin, serum albumin, lysozyme, and other proteins as well. Human milk has a higher proportion of alpha-lactalbumin and the host resistance factors or anti-microbial proteins of human milk, which include lactoferrin, lysozyme and secretory IgA, and account for 75% of the protein in human colostrum as compared with 39% in mature human milk. Additional human milk cells that provide substantial disease resistance in the newly born include lymphocytes, macrophages, and secretory IgA. Lactoferrin is present in relatively high amounts in human milk as is lysozyme and bifidus-stimulating factors. A major objective of this invention is to provide techniques and routines for improving the diet and feeding of infants, particularly very-low-birth-weight infants. By varying the levels of many of these species-specific milk constituents, the invention will result in a myriad of formulations specially suited to a wide variety of medical conditions. [0027]
  • Example 2 Collection of Donor Milk
  • U.S. Pat. No. 4,772,262, which is hereby incorporated by reference in its entirety, is directed to technology for milk removal. As disclosed in that patent, milk yields increase due to the sensory stimulus provided by the patented breast pump equipment. When milk yield increases, the formulation of milk including many of the valuable immunoglobulins also increase along with living cells, such as macrophages and lymphocytes. Lipids also increase and the mother's body responds to the stimulus by producing higher levels of prolactin that will trigger continuing milk supply and the secretion of additional nutrients into her milk. [0028]
  • Example 3 Storage of Donor Milk
  • Previous methods of collecting donor milk failed to recognize the importance of stimulation to the mammary gland as well as collection chambers designed for the anaerobic collection and transfer of donor milk. The invention describes such a method as part of its unique collection, storage and transfer system. Additionally, the preservation of milk components and nutrients is paramount to the success of the invention wherein harvesting of milk cells specific to the species will result in pharmaceutical and nutritional improvements in outcomes for the newly born or immune compromised patient. For that reason, it is important that the container in which the donor milk is stored, will preserve and protect these vital milk constituents from harm due to ultraviolet light and other damaging light rays. A UV coating or additive, applied to the collection bottle during the molding process or afterwards as an exterior coating or sheath will ensure that light degradation does not occur. [0029]
  • Finally, the design of the donor milk collection bottle should make it easy to draw off a sample of the donor milk without compromising the integrity of the milk sample. A proprietary design allows for a twist-turn valve to open and release a small amount of donor milk through a one-way valve into a test vial. The one-way valve prevents any bacteria or other pathogen from contaminating the milk sample. Additionally, a “tear down” design will allow frozen milk to be processed immediately, without the necessity of waiting for the milk to thaw. The tear down feature will provide an easy pull-tab that will strip the container from the frozen block of donor milk. The pull-tab will feature a tag on which a bar code is attached, so that during the tear down process, a “lot” numbering system will track the pooled milk back to their original donors. [0030]
  • Example 4 Transfer of Donor Milk
  • Novel designs for refrigerated transfer units utilizing alternative forms of energy and equipped with temperature indicator recorders ensure that the milk has been maintained under safe conditions. A programmable chip that records temperature variations as well as-handling conditions (rough treatment can compromise milk quality by breaking cell walls), prevents the opening of the transfer case upon arrival at the processing plant. The milk is automatically rejected for quality issues and quarantined for further scrutiny. The transfer unit will contain a programmable chip that stores the contents, origin of contents, date shipped, date received, lot numbers and any other information required for quality control, regulatory or other reasons. [0031]
  • Example 5 Hospital Based Testing and Processing of “Mothers Own” Milk
  • The invention discloses a total quality control system that encompasses both routine and novel procedures and tests. For mothers wishing to provide their own milk for use specifically with their own baby, onsight testing will be done at the hospital. Standard donor screening will be done in accordance with current recommendations and accepted practices. In the present day, no routine testing is done in this case, and frequently the lack of testing causes consternation and concern in the physician with the end result being that babies are being routinely deprived of their mothers' milk. Upon questioning the areas of concern, several neonatologists indicated a concern for the presence of street drugs, disease pathogens and contaminants. To answer this concern, the invention includes a series of quick tests, designed to screen for the presence of the most common pathogens, drugs and contaminants. In order to provide the most efficient form of testing, a series of pumped milk is pooled, mixed and tested. A report is provided to the neonatologist and also placed in the infant's chart. The mothers' milk, intended for her own baby, is housed in the milk laboratory, under optimum storage conditions. Again, a temperature indicator on each container of milk ensures that milk has not been exposed to adverse conditions that may cause degradation or contamination. The temperature indicator is attached to a disposable cap that covers the container. In the event of adverse circumstances, the temperature indicator activates a locking mechanism and the milk is quarantined until further analysis can be done. [0032]
  • Example 6 Onsight (Hospital Based) Delivery Methods for Mothers Own Milk
  • Of special concern in high risk neonatal units, is the loss of milk fat through feeding tubes used to feed very-low-birth-weight, sick or pre-term infants. A special design for extruded tubing employs a method during the manufacturing process, that will eliminate the problem of fat sticking to the inside of the tubing. After extrusion, a heat treatment is applied to the inside of the tubing, via a “pull-through” rod. A heated element, coupled with an anti-static element, of sorts, eliminate the static charge while smoothing the “tackiness” of the interior tubing wall. Coupled with a heated sheath, used during the tube feeding to keep the flow of milk warm, the fat loss can be substantially decreased. A gentle rocking motion, created by a motorized platform on which the enteral pump sits, provides constant agitation and prevents the pumped milk from separating. Additional design features prevent the fat from clinging to the inside of the enteral syringe, in which the pumped milk is contained. A Teflon coating, or alternatively a silicone interior bag or collapsible bag made from a food safe polyvinyl may create additional solutions to this problem. Techniques associated with sequential feeding methods may also mitigate the problems associated with single feed method. By utilizing sequential feeds, the “foremilk” formulation (simulating the composition of the first milk a baby receives during a direct feeding from the breast), is administered. Low in fat, but high in volume, this feed usually takes more time than the higher fat “hindmilk” feed. The hindmilk feed can be then administered from a push syringe specially designed to conserve a large amount of the fat that normally would have stayed in the long tubing associated with the earlier feed. [0033]
  • Example 7 Plant Processing Methods
  • In the practices of this invention the human milk proteins, including the so-called host resistance factors (HRF) of human milk, are prepared by chemically fractionating the same using standard techniques, such as the Cohn method, from pooled donor milk. This method will form the basis for the extraction of the immunoglobulins for the ultimate purpose of purification and processing into nutritional, IV and injectable forms. The present invention discloses a completely closed system for processing. [0034]
  • Under this system, there is no opportunity for contamination. When the donor milk is received at the processing center, a representative sample from each donor lot is tested and cultured. The remaining samples in the lot are transferred to the freezer to hold until the cultures are-read. From the strip-down phase to the spray drying of the final product, all processing occurs within a scaled system. After the lot has been cleared for processing, the frozen containers of milk are placed in an anaerobic chamber where the strip down of the bottle occurs. A filter prevents particles of stripped down plastic bottles from entering the processing system. The frozen chunks of donor milk are thawed, using a slow, continuous heat with a mild churning action. Once thawed, a nutritional analysis is performed to determine specific nutritional levels of the pooled donor milk. Depending upon the desired human milk formulation, the system automatically adjusts the formulation, using validated sources from human milk origin, if augmentation above the levels of the donor milk is desired. Fortification at this point is limited to nutrients that are not adversely affected by heat. As the fortification is being done, the milk is gently churned. The pasteurization process takes place, again, in the same closed system, using the Holder Method of 62.5 C for 20 minutes of 56C for 30 minutes. After pasteurization, the milk is cooled. Second stage fortification occurs at this point, with the addition of previously processed immunoglobulins, as well as selected, 100% screened human milk cells. After processing, final testing is done to determine that the pasteurization process has been successful. [0035]
  • The formulations and methods of the present invention may be embodied in other specific forms without departing from the teachings or essential characteristics of the invention. The described embodiments are therefore to be considered in all respects as illustrative and not restrictive. The scope of the present invention is defined in the following claims, rather than the previous description, and all changes that come within the meaning and range of equivalency of the claims are therefore to be embraced therein. [0036]

Claims (10)

What is claimed is:
1. A nutritional formulation of isolated human milk comprising protective human milk proteins of human milk suitable for infant composition, wherein the nutritional formulation can be directly administered to an infant.
2. The nutritional formulation of claim 1 further comprising human milk cells.
3. The nutritional formulation of claim 2, wherein the human milk cells comprise lymphocytes and macrophages.
4. The nutritional formulation of claim 1, wherein the human milk proteins comprise alpha-lactalbumin, beta-lactoglobulin, lactoferrin, serum albumin, lysozyme and secretory IgA.
5. A method of isolating human milk comprising the steps of:
(a) collecting a sample of human milk from a donor in a collection device, wherein the collection device comprises a computer chip capable of recording temperature variations and handling conditions of the collection device;
(b) storing the sample of human milk obtained from the donor; and
(c) processing the sample of human milk obtained from the donor, wherein processing comprises the steps of:
(i) conducting a nutritional analysis on the sample of human milk;
(ii) conducting a first fortification of the sample of human milk with heat-resistant nutrients;
(iii) pasteurizing the sample of first fortified human milk;
(iv) conducting a second fortification of the sample of human milk with heat-sensitive nutrients; and
(v) testing the sample of fortified human milk to determine whether the pasteurization was successful.
6. The method of claim 5, wherein the computer chip is further capable of recording the origin of the sample, contents of the collection device, volume of the collection device, shipping dates of the sample or lot number of the sample.
7. The method of claim 5, wherein the sample-of human milk is frozen prior to the processing step.
8. The method of claim 5, wherein the collection device further comprises a twist-turn valve to open and release an amount of milk through a one-way valve into a test vial.
9. A system for delivering human milk to an infant comprising:
(a) a feeding tube having an inside and an outside, wherein the inside of the feeding tube is treated to prevent adherence of milk fat to the interior of the feeding tube;
(b) a heated sheath in communication with the outside of the feeding tube; and
(c) an enteral pump removably mounted to a motorized platform, the enteral pump capable of transferring human milk through the feeding tube from a storage container to the infant.
10. The system of claim 9, wherein inside of the feeding tube is coated with silicone.
US10/144,325 2001-05-14 2002-05-13 Method of producing nutritional products from human milk tissue and compositions thereof Abandoned US20020182243A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US29082301P true 2001-05-14 2001-05-14
US10/144,325 US20020182243A1 (en) 2001-05-14 2002-05-13 Method of producing nutritional products from human milk tissue and compositions thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/144,325 US20020182243A1 (en) 2001-05-14 2002-05-13 Method of producing nutritional products from human milk tissue and compositions thereof
US11/012,611 US20050100634A1 (en) 2001-05-14 2004-12-14 Method of producing nutritional products from human milk tissue and compositions thereof
US12/372,376 US7914822B2 (en) 2001-05-14 2009-02-17 Method of producing nutritional products from human milk tissue and compositions thereof
US12/728,811 US20100268658A1 (en) 2001-05-14 2010-03-22 Method for collecting, testing and distributing milk
US13/033,324 US20110206684A1 (en) 2001-05-14 2011-02-23 Method of producing nutritional products from human milk tissue and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/012,611 Continuation US20050100634A1 (en) 2001-05-14 2004-12-14 Method of producing nutritional products from human milk tissue and compositions thereof

Publications (1)

Publication Number Publication Date
US20020182243A1 true US20020182243A1 (en) 2002-12-05

Family

ID=26841905

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/144,325 Abandoned US20020182243A1 (en) 2001-05-14 2002-05-13 Method of producing nutritional products from human milk tissue and compositions thereof
US11/012,611 Abandoned US20050100634A1 (en) 2001-05-14 2004-12-14 Method of producing nutritional products from human milk tissue and compositions thereof
US12/372,376 Active 2022-08-28 US7914822B2 (en) 2001-05-14 2009-02-17 Method of producing nutritional products from human milk tissue and compositions thereof
US13/033,324 Abandoned US20110206684A1 (en) 2001-05-14 2011-02-23 Method of producing nutritional products from human milk tissue and compositions thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/012,611 Abandoned US20050100634A1 (en) 2001-05-14 2004-12-14 Method of producing nutritional products from human milk tissue and compositions thereof
US12/372,376 Active 2022-08-28 US7914822B2 (en) 2001-05-14 2009-02-17 Method of producing nutritional products from human milk tissue and compositions thereof
US13/033,324 Abandoned US20110206684A1 (en) 2001-05-14 2011-02-23 Method of producing nutritional products from human milk tissue and compositions thereof

Country Status (1)

Country Link
US (4) US20020182243A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026879A1 (en) * 2004-09-10 2006-03-16 Medela Holding Ag Method for analysing and treating human milk and system therefore
EP1637880A1 (en) * 2004-09-17 2006-03-22 Medela Holding AG Method for analysing and treating human milk and system therefor
WO2007044476A2 (en) * 2005-10-06 2007-04-19 Saint Simeon Lda Lysozyme fortified milk and milk products
US20070098863A1 (en) * 2005-09-23 2007-05-03 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
EP1791444A1 (en) 2004-09-10 2007-06-06 Medela Holding AG Human milk fortifiers and methods for their production
US20070203802A1 (en) * 2005-09-23 2007-08-30 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
WO2007112607A1 (en) * 2006-03-30 2007-10-11 Medela Holding Ag Method for the treatment of human milk
US20080075819A1 (en) * 2006-09-22 2008-03-27 Medela Holding Ag Treatment of mother's milk
US20080124430A1 (en) * 2006-11-29 2008-05-29 Medo Elena M Human Milk Compositions and Methods of Making and Using Same
US20080227101A1 (en) * 2005-09-20 2008-09-18 Medo Elena M Methods for testing milk
US20090258121A1 (en) * 2001-05-14 2009-10-15 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
US20100183769A1 (en) * 2009-01-21 2010-07-22 Christensen Robert D Infant formula compositions for neonates lacking mother's own colostrum and method of making
US20100268658A1 (en) * 2001-05-14 2010-10-21 Prolacta Bioscience Method for collecting, testing and distributing milk
US20100280115A1 (en) * 2006-12-08 2010-11-04 Medo Elena M Compositions of human lipids and methods of making and using same
US20140322425A1 (en) * 2005-03-09 2014-10-30 Abbott Laboratories Concentrated human milk fortifier liquid
US8927027B2 (en) 2008-12-02 2015-01-06 Prolacta Bioscience Human milk permeate compositions and methods of making and using same
WO2015154665A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them
US9980507B2 (en) 2010-11-02 2018-05-29 Abbott Laboratories Stable concentrated liquid human milk fortifier
US20190053508A1 (en) * 2006-08-30 2019-02-21 Prolacta Bioscience, Inc. Methods of obtaining sterile milk and compositions thereof
US10506818B2 (en) 2011-08-03 2019-12-17 Prolacta Bioscience, Inc. Microfiltration of human milk to reduce bacterial contamination

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014241754B2 (en) * 2013-03-13 2017-11-30 Prolacta Bioscience, Inc. High fat human milk products
AU2016381834A1 (en) * 2015-12-30 2018-06-28 Prolacta Bioscience, Inc. Human milk products useful in pre- and post-operative care

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567898A (en) 1945-03-19 1951-09-11 Separator Ab Method of standardizing cream
DE3040171C2 (en) 1980-10-24 1986-05-22 Max-Josef Dr.-Ing. Zuerich Ch Schoenhuber
US4362697A (en) * 1981-04-20 1982-12-07 Miles Laboratories, Inc. Homogeneous specific binding assay test device having copolymer enhancing substance
US4772262A (en) * 1985-04-16 1988-09-20 Natural Technologies, Inc. Portable electric breast pump
US4762822A (en) * 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
US5310893A (en) * 1986-03-31 1994-05-10 Hoffmann-La Roche Inc. Method for HLA DP typing
NZ228690A (en) * 1988-04-13 1991-10-25 Snow Brand Milk Prod Co Ltd Continuous production of cheese curds from ultrafiltrated milk
US6020015A (en) * 1988-09-22 2000-02-01 Gaull; Gerald E. Infant formula compositions and nutrition containing genetically engineered human milk proteins
US5334822A (en) 1990-05-21 1994-08-02 Universal Computer Technologies Inc. Method and system for inventoring a distributed plurality of items on a supply
DE4018468C2 (en) 1990-06-08 1992-12-10 Ultrakust Electronic Gmbh, 8375 Ruhmannsfelden, De
CA2108580A1 (en) * 1991-05-31 1992-12-01 Arthur J. Ammann Treatment of hiv-associated immune thrombocytopenic purpura
US5169766A (en) * 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5616483A (en) * 1992-06-11 1997-04-01 Aktiebolaget Astra Genomic DNA sequences encoding human BSSL/CEL
US6056978A (en) * 1992-06-16 2000-05-02 Stolle Milk Biologics, Inc. Use of hyperimmune milk to prevent suppression of T-lymphocyte production
CA2148261A1 (en) 1992-10-30 1994-05-11 Jerry A. Peterson Anti-diarrheic product and method of treating rotavirus-associated infection
US5983198A (en) 1996-04-23 1999-11-09 Novus International, Inc. Integrated system monitoring use of materials, controlling and monitoring delivery of materials and providing automated billing of delivered materials
US5798266A (en) 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6194009B1 (en) 1996-11-22 2001-02-27 Princeton Nutrition, Llc Refrigeration-shelf-stable ultra-pasteurized or pasteurized infant formula
US6652900B2 (en) 1997-03-14 2003-11-25 Tetra Laval Holdings & Finance S.A. Method and plant for producing a sterile milk product
US6017511A (en) * 1997-05-30 2000-01-25 Resolution Pharmaceuticals Inc. Glycopeptide-chelator conjugates
GB9713597D0 (en) * 1997-06-28 1997-09-03 Sec Dep Of The Home Department Improvements in and relating to forensic identification
US6004288A (en) * 1998-11-24 1999-12-21 Hochstedler; Judy R. Breast pump
US20020155445A1 (en) 1999-12-16 2002-10-24 Jarvik Jonathan W. Methods and products for peptide based DNA sequence identification and analysis
US6471660B1 (en) 1999-01-21 2002-10-29 Chandice Covington Method and apparatus for measuring factors in mammary fluids
US20010049096A1 (en) * 1999-03-23 2001-12-06 Stephen J. Brown Sample identification with analyte determination
US6294206B1 (en) 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6183803B1 (en) 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
US6780987B1 (en) 1999-12-10 2004-08-24 Trustees Of The Tufts College β-cap73 control of normal and abnormal cell migration
US6670124B1 (en) * 1999-12-20 2003-12-30 Stemcyte, Inc. High throughput methods of HLA typing
CN1299771C (en) * 2000-11-15 2007-02-14 冯泰拉合作集团有限公司 Colorstrum-based composition
WO2002090572A2 (en) 2001-05-09 2002-11-14 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
US20020182243A1 (en) * 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
US20100268658A1 (en) * 2001-05-14 2010-10-21 Prolacta Bioscience Method for collecting, testing and distributing milk
US6866994B2 (en) 2001-05-30 2005-03-15 Neomatrix, Llc Noninvasive intraductal fluid diagnostic screen
US20030093171A1 (en) 2001-07-19 2003-05-15 Creative Edge Design Group, Ltd. Flexible label printing assembly
US6875459B2 (en) 2001-09-10 2005-04-05 Henry B. Kopf Method and apparatus for separation of milk, colostrum, and whey
US6910594B2 (en) * 2002-11-19 2005-06-28 The First Years Inc. Method and apparatus for storing milk
WO2004112509A2 (en) * 2003-06-23 2004-12-29 Nestec S.A. Nutritional formula for optimal gut barrier function
CA2530170A1 (en) 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
CA2542612A1 (en) * 2003-10-14 2005-04-21 Kingston Henry Gordon Mills Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
JP2008512656A (en) 2004-09-10 2008-04-24 メデラ ホールディング アーゲー Human milk analysis and processing method and system therefor
US20080187619A1 (en) * 2004-09-10 2008-08-07 Medela Holding Ag Human Milk Fortifiers and Methods for Their Production
US20060115558A1 (en) 2004-11-30 2006-06-01 Jean-Claude Lamothe Method of production and control of animal derived food products and derivatives thereof
CA2537452C (en) 2005-03-09 2013-12-24 Abbott Laboratories Concentrated human milk fortifier liquid
US20060233915A1 (en) 2005-04-15 2006-10-19 Bristol-Myers Squibb Company Liquid nutritional product to supplement human milk
BRPI0616323A2 (en) 2005-09-20 2011-06-14 Prolacta Bioscience Inc Method for determining whether a donated mammary fluid was obtained from a specific individual
US20070203802A1 (en) 2005-09-23 2007-08-30 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
US20070098863A1 (en) 2005-09-23 2007-05-03 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
JP5074514B2 (en) 2006-11-29 2012-11-14 プロラクタ バイオサイエンス,インコーポレイテッド Human milk composition and methods of making and using it
ES2634613T3 (en) 2006-08-30 2017-09-28 Prolacta Bioscience, Inc. Methods of obtaining sterile milk and compositions thereof
CN101631469B (en) 2006-12-08 2014-04-02 普罗莱克塔生物科学公司 Compositions of human lipids and methods of making and using same
US20080254165A1 (en) * 2007-04-12 2008-10-16 Rashid Patel Novel manufacturing process for milk acid

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206684A1 (en) * 2001-05-14 2011-08-25 Prolacta Bioscience Inc. Method of producing nutritional products from human milk tissue and compositions thereof
US20100268658A1 (en) * 2001-05-14 2010-10-21 Prolacta Bioscience Method for collecting, testing and distributing milk
US20090258121A1 (en) * 2001-05-14 2009-10-15 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
US7914822B2 (en) 2001-05-14 2011-03-29 Prolacta Bioscience, Inc. Method of producing nutritional products from human milk tissue and compositions thereof
JP2008512656A (en) * 2004-09-10 2008-04-24 メデラ ホールディング アーゲー Human milk analysis and processing method and system therefor
WO2006026879A1 (en) * 2004-09-10 2006-03-16 Medela Holding Ag Method for analysing and treating human milk and system therefore
EP1791444A1 (en) 2004-09-10 2007-06-06 Medela Holding AG Human milk fortifiers and methods for their production
US20080187619A1 (en) * 2004-09-10 2008-08-07 Medela Holding Ag Human Milk Fortifiers and Methods for Their Production
US20080118615A1 (en) * 2004-09-10 2008-05-22 Medela Holding Ag Method for Analysing and Treating Human Milk and System Therefore
JP2008512398A (en) * 2004-09-10 2008-04-24 メデラ ホールディング アーゲー Human milk fortifier and its manufacturing method
EP1637880A1 (en) * 2004-09-17 2006-03-22 Medela Holding AG Method for analysing and treating human milk and system therefor
US20140322425A1 (en) * 2005-03-09 2014-10-30 Abbott Laboratories Concentrated human milk fortifier liquid
US8628921B2 (en) 2005-09-20 2014-01-14 Prolacta Bioscience Inc. Methods for testing milk
US20080227101A1 (en) * 2005-09-20 2008-09-18 Medo Elena M Methods for testing milk
US8278046B2 (en) 2005-09-20 2012-10-02 Prolacta Bioscience Methods for testing milk
US7943315B2 (en) 2005-09-20 2011-05-17 Prolacta Bioscience, Inc. Methods for testing milk
US20070098863A1 (en) * 2005-09-23 2007-05-03 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
US20070203802A1 (en) * 2005-09-23 2007-08-30 Prolacta Bioscience, Inc. Method for collecting, testing and distributing milk
WO2007044476A3 (en) * 2005-10-06 2007-11-08 Saint Simeon Lda Lysozyme fortified milk and milk products
WO2007044476A2 (en) * 2005-10-06 2007-04-19 Saint Simeon Lda Lysozyme fortified milk and milk products
WO2007112607A1 (en) * 2006-03-30 2007-10-11 Medela Holding Ag Method for the treatment of human milk
US20100215797A1 (en) * 2006-03-30 2010-08-26 Charles Czank Treatment of Human Milk
US20190053508A1 (en) * 2006-08-30 2019-02-21 Prolacta Bioscience, Inc. Methods of obtaining sterile milk and compositions thereof
US20140093634A1 (en) * 2006-08-30 2014-04-03 Prolacta Bioscience, Inc. Human milk compositions and methods of making and using same
US20080075819A1 (en) * 2006-09-22 2008-03-27 Medela Holding Ag Treatment of mother's milk
US8545920B2 (en) * 2006-11-29 2013-10-01 Prolacta Bioscience Inc. Human milk compositions and methods of making and using same
US20080124430A1 (en) * 2006-11-29 2008-05-29 Medo Elena M Human Milk Compositions and Methods of Making and Using Same
US8377445B2 (en) 2006-12-08 2013-02-19 Prolacta Bioscience, Inc. Compositions of human lipids and methods of making and using same
US8821878B2 (en) 2006-12-08 2014-09-02 Prolacta Bioscience, Inc. Compositions of human lipids and methods of making and using same
US20100280115A1 (en) * 2006-12-08 2010-11-04 Medo Elena M Compositions of human lipids and methods of making and using same
US8927027B2 (en) 2008-12-02 2015-01-06 Prolacta Bioscience Human milk permeate compositions and methods of making and using same
US20100183769A1 (en) * 2009-01-21 2010-07-22 Christensen Robert D Infant formula compositions for neonates lacking mother's own colostrum and method of making
US9980507B2 (en) 2010-11-02 2018-05-29 Abbott Laboratories Stable concentrated liquid human milk fortifier
US10506818B2 (en) 2011-08-03 2019-12-17 Prolacta Bioscience, Inc. Microfiltration of human milk to reduce bacterial contamination
WO2015154665A1 (en) * 2014-04-09 2015-10-15 Nestle (China) Ltd. Gender specific synthetic nutritional compositions and nutritional systems comprising them

Also Published As

Publication number Publication date
US20050100634A1 (en) 2005-05-12
US7914822B2 (en) 2011-03-29
US20090258121A1 (en) 2009-10-15
US20110206684A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
Underwood Human milk for the premature infant
Lee et al. Oropharyngeal colostrum administration in extremely premature infants: an RCT
Verhasselt Neonatal tolerance under breastfeeding influence
Bullen et al. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants
Walker Role of nutrients and bacterial colonization in the development of intestinal host defense
Sangild et al. Invited review: the preterm pig as a model in pediatric gastroenterology
Edde et al. Lactoferrin protects neonatal rats from gut-related systemic infection
Wight Donor human milk for preterm infants
Hurley et al. Perspectives on immunoglobulins in colostrum and milk
Langridge Edible vaccines
Meier et al. Supporting breastfeeding in the neonatal intensive care unit: Rush Mother’s Milk Club as a case study of evidence-based care
ES2665745T3 (en) Apparatus and method for providing measured or dosed amounts of an ingredient, in particular for customized nutrition for babies
Schanler The use of human milk for premature infants
Lau et al. Oral feeding in infants
Hanson et al. The role of breastfeeding in prevention of neonatal infection
EP1168929B2 (en) Powdered human milk fortifier
Seigel et al. Early administration of oropharyngeal colostrum to extremely low birth weight infants
Heiman et al. Benefits of maternal and donor human milk for premature infants
Lantieri et al. Feasibility, reproducibility, risks and benefits of face transplantation: a prospective study of outcomes
Oddy The impact of breastmilk on infant and child health
Pereira et al. Hyperalimentation-induced cholestasis: increased incidence and severity in premature infants
Schanler Suitability of human milk for the low-birthweight infant
Stuart-Macadam Biocultural perspectives on breastfeeding
Patton Milk: Its remarkable contribution to human health and well-being
Warner The early life origins of asthma and related allergic disorders

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION

AS Assignment

Owner name: PROLACTA BIOSCIENCE, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDO, ELENA MARIA;REEL/FRAME:020436/0771

Effective date: 20080110